A global pharmaceutical client preparing to launch a next-generation antihistamine across Southeast Asia engaged Lynx Analytics to generate real-world market intelligence from digital sources. With a competitive antihistamine market dominated by well-established molecules and a patient population that actively discusses medication choices online, the client needed to understand exactly how patients and healthcare professionals perceived the antihistamine — and where it could carve a credible, differentiated position.
The existing evidence base for the antihistamine was largely clinical. What was missing was the unfiltered voice of patients and prescribers: which attributes they valued, which competitors they discussed, and what drove switching behavior in the real world. The client's prior market research had identified initial hypotheses, but lacked the granularity and scale that only large-scale digital analysis could provide.
Lynx Analytics designed and executed a comprehensive social listening framework across Thailand and the Philippines, analyzing approximately 139,000 online mentions spanning patient forums, HCP discussions, influencer content, and educational resources. Using a tiered search architecture of around 2,000 curated phrases and a custom LLM classification pipeline, the engagement delivered granular sentiment analysis by molecule and attribute, competitive perception mapping, and concrete positioning and messaging recommendations.
The Southeast Asian antihistamine market is large, fragmented, and highly driven by consumer behavior. Patients routinely self-medicate, discuss drug experiences on public forums and social platforms, and actively compare brands by name. In Thailand and the Philippines, online conversations about allergies and antihistamines span everything from Pantip forum threads and Lemon8 influencer posts to HCP blogs and pharmacy comparison sites — generating a rich, largely untapped body of real-world evidence.
The client's antihistamine product — a fourth-generation molecule with strong clinical efficacy and a favorable non-sedating profile — was preparing for a new-format launch in both markets. The format's key promise — fast dissolution, no water needed, portable convenience — aligned naturally with on-the-go lifestyles. However, it carried a known adoption barrier: a strict empty-stomach dosing requirement. Understanding how patients weighed these trade-offs was essential to shaping a credible launch strategy.
The client needed to move from clinical confidence to commercial conviction — and that required understanding the market through the eyes of patients and prescribers, not trial data.
Low Digital Visibility
Despite strong clinical credentials, the antihistamine represented only a small fraction of total online antihistamine mentions — under 5% of approximately 139,000 total signals. Legacy molecules — cetirizine, loratadine, and fexofenadine — dominated the digital conversation. The antihistamine had yet to establish the 'mental availability' that drives consumer switching at scale.
Fragmented and Unstructured Evidence
The digital signal existed — patients were posting, comparing, and recommending — but it was scattered across dozens of platforms, in multiple languages, and mixed with noise. No structured analysis had been conducted to extract sentiment, attribute-level perception, or competitive positioning signals at scale.
A Positioning Tension to Resolve
The proposed 'on-the-go' messaging was intuitive — but risked being undermined by the antihistamine's empty-stomach dosing requirement, which patients in both markets flagged as a genuine inconvenience. The client needed to understand how patients weighed this barrier before committing to a positioning platform.
Lynx Analytics designed and delivered an end-to-end social listening and intelligence platform, purpose-built for the Southeast Asian antihistamine market across Thailand and the Philippines.
Tiered Search Architecture
Lynx Analytics built an eight-tier search framework combining brand names, molecule names, colloquial symptom terminology, comparison queries, and long-tail phrases. Using a list of brand and competitor names provided by the client team, we curated approximately 2,000 search phrases per market. The top 20 brands in each market received deep multi-tier coverage; brands ranked 21–50 received limited search; remaining brands were covered by keyword search only.
Web Crawling and Filtration
Search phrases yielded over 1,200 URLs in Thailand and 2,100 in the Philippines. A multi-stage filtration pipeline removed duplicates, cached files, and paywalled content — reducing the corpus to approximately 73 and 289 high-quality analyzable URLs respectively, focused on genuine patient and HCP conversation.
LLM Sentiment Classification
All text was extracted, translated where required, and parsed using detailed classification prompts. Each mention was tagged with molecule, keyword topic, and a sentiment score, enabling quantitative comparison across 15 tracked attributes — from symptom control and drowsiness to affordability, dosing schedule, and ease of administration.
Competitive Intelligence Synthesis
Lynx Analytics produced a full competitive perception map across all major antihistamine molecules. The antihistamine's 'premium step-up' positioning — chosen when others fail, valued for its zero-sedation profile — emerged directly from the data.
The engagement was structured as one component of a broader evidence generation program that included KOL interviews, patient interviews, and a modified Delphi survey. The social listening workstream ran in parallel, with data collection and analysis completed ahead of the round table discussion. The client's existing relationship with regional data infrastructure and market intelligence platforms enabled efficient data acquisition, with the Lynx Analytics team focusing analytical effort on classification, synthesis, and insight generation rather than raw data engineering.
A key validation moment came at the round table itself. When the social listening outputs were presented to KOLs and HCPs, the findings resonated immediately — the patient language, the frustrations with legacy molecules, and the switching triggers that the digital analysis had surfaced all aligned closely with what clinicians had been hearing directly from patients in practice. This independent convergence between large-scale digital signal and frontline clinical experience gave the client team strong confidence in the evidence base ahead of launch.
The analysis transformed the client's understanding of the antihistamine opportunity from a clinical narrative to a market reality. Where internal assumptions had positioned the antihistamine primarily as a convenience play, the data revealed a more nuanced picture: patients valued the antihistamine most for its efficacy in difficult cases and its genuinely non-sedating profile — attributes that commanded premium positioning and justified the price differential.
The competitive analysis surfaced actionable gaps: the antihistamine's low share of digital voice relative to cetirizine and loratadine was not a reflection of patient dissatisfaction, but of low awareness and limited digital activation. Patients who had used it were vocal advocates — the opportunity was to get it into more high-intent conversations.
What Becomes Possible When Clinical Confidence Meets Real-World Evidence
By systematically harvesting and analyzing the digital conversations of patients and healthcare professionals across two markets, Lynx Analytics gave the client something no clinical trial can provide: an unfiltered view of how their product lives in the minds of the people who use it.
The result was not just market intelligence — it was a strategic foundation for a launch built on what patients actually value, not what the industry assumes they do.
From signal to strategy — evidence that drives decisions.